
    
      Retrospective analyses of the safety and effectiveness data in the Obalon US Commercial
      Registry reported by participating clinics through August 28, 2018 from patients who started
      the Obalon therapy from January to December 2017 to represent the first year of
      commercialization. All patients included in the safety and efficacy analyses must have data
      through balloon removal and a starting BMI greater than or equal to 25, the definition of
      overweight and obese patients.
    
  